Impact of an integrated oral chemotherapy program on patient adherence

Morgan, Katherine P.; Muluneh, Benyam; Deal, Allison M.; Amerine, Lindsey B.

doi:10.1177/1078155217703792

Cited by 29 publications

(34 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study that evaluated the effectiveness of an integrated oral chemotherapy program concluded that patients who were called twice a month to discuss their oral oncolytic had better adherence rates to their therapy than did patients who were not pre-emptively contacted. 57 …”

Section: Monitoring and Follow-upmentioning

confidence: 99%

2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard

Mackler

Segal

Muluneh

et al. 2019

JOP

Self Cite

View full text Add to dashboard Cite

PURPOSE: The aim of the current work was to present a pharmacy practice standard from the Hematology/Oncology Pharmacy Association (HOPA) on the management of oral oncolytic therapy. METHODS: The HOPA Standards Committee organized a work group of oncology pharmacist specialists to create a pharmacy practice standard for the management of oral oncolytic therapy that describes the pharmacist’s role on the cancer care team, provides examples of practice tools and resources, summarizes current data related to outcomes, and discusses opportunities to enhance the care of patients with cancer who receive oral oncolytic therapy. We reviewed primary literature, including currently published oral oncolytic guidelines and HOPA’s Scope of Hematology/Oncology Pharmacy Practice. RESULTS: Management of oral oncolytic therapy was divided into the following primary areas: prescribing, education, dispensing and distribution, and monitoring and follow-up. Pharmacists’ roles were summarized in each area with a focus on interprofessional collaboration, communication, patient safety, and quality of patient care. Standards describe the best practices in each area ( Table 1 ). CONCLUSION: Multiple opportunities exist for pharmacists to enhance the care of patients with cancer who receive oral oncolytics through collaboration with oncology care team members. The role of the oncology pharmacist in the care of this patient population is critical given the complexities related to cost, tolerability, and safety of oral oncolytic medications; issues of access; and the monitoring and follow-up of patients receiving this therapy.

show abstract

Section: Monitoring and Follow-upmentioning

confidence: 99%

2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard

Mackler

Segal

Muluneh

et al. 2019

JOP

Self Cite

View full text Add to dashboard Cite

show abstract

“…Additionally, improved adherence has been observed among patients who follow up with a pharmacist within the first 3 months of oral chemotherapy [24].Results of numerous studies have demonstrated the impact of a pharmacist on adherence rates among patients on oral anticancer treatment. New research assessing the feasibility of an adaptive oral chemotherapy program showed that patients who were called to evaluate their oral oncolytic twice a month had greater adherence rates than patients who were not proactively approached [27].For patients with chronic immune thrombocytopenia, pharmacists may collaborate with the treatment team to offer continuous adherence assessments.…”

Section: Oncology Pharmacists'role In Patient Carementioning

confidence: 99%

The Role of Oncology Pharmacists in optimizing patient care in Chronic Immune Thrombocytopenia

2021

EJMCM

View full text Add to dashboard Cite

Immune thrombocytopenia or ITP is an autoimmune disorder in which the body creates autoantibodies against its thrombocytes or platelets that are destroyed, resulting in purpura or minor bleeding spots under the surface. It is most often found in cancer patients and is of growing concern.While the main causes of thrombocytopenia in cancer patients are chemotherapy and radiation, other aetiologies should also be considered in patients suffering from this debilitating disease. Thrombocytopenia causes a variety of complications in the treatment of cancer patients and therefore pharmacists need to be familiar with epidemiology, pathophysiology, risk factors, diagnostic methods, and emerging therapeutic options for chronic immune thrombocytopenia to help oncologists identify and implement realistic treatment measures for chronic immune thrombocytopenia patients undergoing cancer treatment.The objective of this review is to provide a brief overview of chronic immune thrombocytopenia and various strategies for the clinical management of the disease

show abstract

“…Adherence to OA is an important indicator of therapeutic response 2,3,6,8,9 . Several studies have shown that poor adherence may affect treatment efficacy, toxicity, public health expenditures, patient survival time, and increase mortality risk [1][2][3][5][6][7][8][9][10][11][12] . For women with hormone receptor-positive breast cancer, for example, mortality can reach up to 49% of nonadherents 8 .…”

Section: Introductionmentioning

confidence: 99%

Oral Antineoplastics: Treatment Adherence and Medication Beliefs

Andrzejevski

Padilha

Félix

et al. 2021

Rev. Bras. Cancerol.

View full text Add to dashboard Cite

Introdução: A adesão aos antineoplásicos orais (AO) e um importante indicador de resposta terapêutica relacionada a fatores pessoais, sociais e estruturais. Objetivo: Determinar as taxas de adesão aos AO, investigando possíveis fatores de risco para a não adesão, e avaliar as crenças dos pacientes sobre medicamentos, identificando oportunidades de intervenção farmacêutica. Método: Estudo analítico realizado com pacientes com câncer em uso de AO em 2015. Escala de Adesão e Recarga dos Medicamentos (ARMS) e Questionário de Crenças sobre Medicamentos (BMQ) foram aplicados para avaliar a adesão e crenças sobre medicamentos e tratamento. Os testes de Mann-Whitney, qui-quadrado e exato de Fisher foram usados para análise de dados. Resultados: Foram entrevistados 222 pacientes, com taxa de adesão de 92,8%, segundo o ARMS e 84,7%, segundo o BMQ, no qual as crenças de necessidade excederam as preocupações com o tratamento e o uso de AO. Renda familiar, interrupção do tratamento, número e causas das interrupções, depressão e razão de posse de medicamentos foram os fatores de risco identificados. A comparação dos domínios do BMQ demostrou que, no grupo aderente, as crenças dos pacientes sobre a necessidade do medicamento excederam suas preocupações quanto a isso. Conclusão: Considerar as crenças do paciente e um fator decisivo para compreender os riscos relacionados a não adesão, bem como para definir estratégias para lidar com ela.

show abstract

Impact of an integrated oral chemotherapy program on patient adherence

Cited by 29 publications

References 11 publications

2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard

2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard

The Role of Oncology Pharmacists in optimizing patient care in Chronic Immune Thrombocytopenia

Oral Antineoplastics: Treatment Adherence and Medication Beliefs

Contact Info

Product

Resources

About